ScholarLens Back to search
2021•Research SquareOpen access

Cost-Utility Analysis of Palbociclib, Ribociclib and Letrozole in the First Line Treatment of Metastatic Breast Cancer in Iran Using Partitioned Survival Model

Ali Darvishi, Rajabali Daroudi, Aliakbar Fazaeli

Open full text 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Palbociclib, Letrozole, Metastatic breast cancer, Oncology, Medicine, Cancer, Breast cancer, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Cost-Utility Analysis of Palbociclib, Ribociclib and Letrozole in the First Line Treatment of Metastatic Breast Cancer in Iran Using Partitioned Survival Model — Research Paper | ScholarLens